2016-04-07 18:08:34 UTC

FDA Approves New Biosimilar for IBD Patients

April 11, 2016

The biosimilar version of Remicade was approved for moderate to severe Crohn's disease and ulcerative colitis patients.

FDA has approved a new biosimilar version of the drug Remicade® (infliximab), making it the second biosimilar to receive approval. The decision came two months after the FDA Arthritis Advisory Committee voted 21 to three to recommend approval of the biosimilar. The new product, originally developed by South Korean company Celltrion, will be marketed by Pfizer under the brand name InflectraTM. The European Commission approved licensure in September 2013.  

FDA approved Inflectra for the following conditions:

  • Adult and pediatric patients age six and older with moderate to severe Crohn’s disease who have had an inadequate response to conventional therapy.
  • Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
  • Patients with moderately to severely active rheumatoid arthritis in combination with methotrexate.
  • Patients with active ankylosing spondylitis (arthritis of the spine).
  • Patients with active psoriatic arthritis.
  • Adult patients with chronic severe plaque psoriasis.  

An announcement released by FDA noted that the decision to approve Inflectra was based on evidence including structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data. The approval does not give the drug interchangeability status, which is a higher level of review than for biosimilarity.  

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.